Clinical Trial Update: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

View source ↗

Summary

The clinical trial evaluating BETaferon for quality of life in early relapsing-remitting multiple sclerosis in Korea has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Betaferon (interferon beta-1b)

Snippet

Sponsor: Bayer | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: WITHDRAWN